2025-523658-15-00招募中3 期
J3R-MC-YDAF - A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants with Obesity or Overweight, and Type 2 Diabetes
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 297
- 试验地点
- 34
- 主要终点
- Percent Change from Baseline in Body Weight [Time Frame: Baseline, Week 64]
研究概览
简要总结
To demonstrate that eloralintide is superior to placebo for change in body weight.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Have type 2 diabetes
- •Be on stable treatment for type 2 diabetes
- •Have a BMI ≥ 27 kg/m2
- •Have a stable body weight (<5% body weight change) for 90 days prior to screeninG
排除标准
- •Participants must not have had or are planning to have surgery, an endoscopic procedure, and/or device-based therapy for weight loss (with exceptions)
- •Have type 1 diabetes
- •Have taken certain medications for blood sugar within 90 days prior to screening
- •Have had a serious heart condition within 90 days prior to screening
- •Have taken medications or alternative remedies intended for weight loss within 90 days prior to screening
研究组 & 干预措施
Placebo to match ly
Placebo
干预措施: Placebo to match ly (Drug)
Eloralintide, Eloralintide, Eloralintide, Eloralintide
Test
干预措施: Eloralintide (Drug)
结局指标
主要结局
Percent Change from Baseline in Body Weight [Time Frame: Baseline, Week 64]
Percent Change from Baseline in Body Weight [Time Frame: Baseline, Week 64]
次要结局
未报告次要终点
研究者
EU_lilly_clinical_trials@lilly.com
Scientific
Eli Lilly & Co.
研究点 (34)
Loading locations...
相似试验
招募中
3 期
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes ( ENLIGHTEN-1).OverweightObesity2025-523657-34-00Eli Lilly & Co.254
招募中
3 期
A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight (ENLIGHTEN-3)Obesity2025-523769-11-00Eli Lilly & Co.169
招募中
3 期
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 DiabetesObesityObesityNCT07321886Eli Lilly and Company1,980
招募中
3 期
A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)ObesityType 2 Diabetes2022-502837-24-00Eli Lilly & Co.390
招募中
3 期
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly IncretinObesityNCT07392190Eli Lilly and Company900